781 completed, 157 terminated, 87 recruiting, 75 active not recruiting. 1153 Phase 1, 268 Phase 2.
Follow Merck Sharp & Dohme LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014) Ulonivirine - Hepatic Insufficiency | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 22 | 2027-01-22 | 2026-07-16 |
| A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) MK-7602, Pyronaridine - Healthy | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 24 | 2027-01-04 | 2026-11-05 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) Sacituzumab tirumotecan, Rescue medication, Docetaxel - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 290 | 2026-12-14 | 2026-11-02 |
| A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) MK-6916 - Healthy, Renal Impairment | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 32 | 2026-12-11 | 2026-11-06 |
| Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory Papillomatosis* GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) - Recurrent Respiratory Papillomatosis (RRP) | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University | 50 | 2026-12-01 | 2026-10-22 |
| A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) Midazolam, Rosuvastatin, MK-6916 - Healthy | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 18 | 2026-11-30 | 2026-10-07 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) MK-6255, CD8 PET Tracer, Acetaminophen - Ovarian Neoplasms, Endometrial Neoplasms | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 80 | 2026-11-13 | 2026-10-13 |
| A Clinical Trial of V175 and V175A in Healthy Adults V175, V175A, Control Vaccine - Lower Respiratory Tract Infection | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 564 | 2026-10-21 | 2026-11-06 |
| A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 132 | 2026-10-20 | 2026-10-27 |
| A Clinical Trial to Evaluate the Effects of MK-4646 on Rosuvastatin in Healthy Participants (MK-4646-007) Rosuvastatin, MK-4646 - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 16 | 2026-09-25 | 2026-11-04 |
| A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer Patritumab deruxtecan, Trastuzumab deruxtecan - Hormone Receptor Positive, HER2-low or HER2-ultralow | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | 220 | 2026-09-17 | 2026-10-01 |
| A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) MK-1406 - Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2026-09-10 | 2026-10-27 |
| A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) Nemtabrutinib - Severe Renal Impairment, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-09-08 | 2026-09-23 |
| A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) MK-8527, Rifampin - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 14 | 2026-09-01 | 2026-08-03 |
| A Clinical Trial of Enlicitide (MK-0616) Formulations in Healthy Participants (MK-0616-044) Enlicitide - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 30 | 2026-08-31 | 2026-09-18 |
| A Clinical Trial of Multiple Formulations of MK-4082 in Healthy Overweight and Obese Participants (MK-4082-007) MK-4082 Formulation 1 (F1), MK-4082 Formulation 2 (F2), MK-4082 Formulation 4 (F4) - Healthy | Phase 1 | Active not recruiting | Merck Sharp & Dohme LLC | 48 | 2026-08-25 | 2026-09-23 |
| A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019) Ulonivirine, Methadone - Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 14 | 2026-08-17 | 2026-09-23 |
| A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) MK-1403 formulation (FM) 1 + additive, MK-1403 FM2 + additive - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2026-08-14 | 2026-10-09 |
Showing 20 of 1153. Sign in to see all of them.
Neoplasms (103) · Carcinoma, Non-Small-Cell Lung (97) · Melanoma (68) · Diabetes Mellitus, Type 2 (57) · Neoplasm Metastasis (48) · Breast Neoplasms (47) · Colorectal Neoplasms (43) · Parkinson Disease 4, Autosomal Dominant Lewy Body (43) · Carcinoma, Renal Cell (42) · Hepatitis C (34) · Ovarian Neoplasms (33) · Squamous Cell Carcinoma of Head and Neck (30) · Lymphoma (27) · Triple Negative Breast Neoplasms (27) · Lung Neoplasms (26)
pembrolizumab (375) · Vorinostat (61) · Carboplatin (41) · Paclitaxel (33) · Cisplatin (27) · Gemcitabine (24) · Pemetrexed (23) · lenvatinib (21) · MK-0616 (20) · Dexamethasone (19) · ridaforolimus (19) · Radiotherapy (17) · Bevacizumab (16) · Raltegravir Potassium (16) · Sitagliptin Phosphate (16)
United States (575) · Spain (105) · South Korea (80) · Australia (73) · United Kingdom (72) · Canada (71) · France (71) · Germany (58) · Israel (56) · Italy (53) · Japan (52) · Netherlands (43) · China (41) · Taiwan (39) · Chile (36)
Amy Schaberg, BSN (4) · Peter Reese, MD, MSCE (3) · Andres McAllister, PhD (2) · Angela Kashuba, PharmD (2) · David P Nicolau, PharmD (2) · Dean Fennell (2)
PMID 33813736, PMID 34213819, PMID 27072496, PMID 28647166, PMID 31395089, PMID 35101941, PMID 18068514, PMID 19833861, PMID 20175977, PMID 21475673, PMID 22192849, PMID 23013236, PMID 23497415, PMID 24782116, PMID 25830322, PMID 27561272, PMID 28347318, PMID 29545266, PMID 29703432, PMID 30689507, PMID 32337660, PMID 35596791, PMID 37598000, PMID 39601078, PMID 41830320, PMID 12082455, PMID 12082456, PMID 15324521, PMID 15704203, PMID 17145826, PMID 17468348, PMID 17654304, PMID 18058098, PMID 18202410, PMID 18297527, PMID 19221403, PMID 19491335, PMID 19605598, PMID 19643947, PMID 19691426, PMID 19717722, PMID 19817748, PMID 19887475, PMID 20386909, PMID 20395869, PMID 20398037, PMID 20509027, PMID 20563869, PMID 20854108, PMID 20921313
2023 (40), 2015 (18), 2017 (16), 2018 (16), 2019 (14), 2016 (12), 2009 (11), 2014 (11), 2025 (11), 2008 (4), P30CA138292 (3), P30CA060553 (2), P30CA093373 (2), 2005 (1), K08CA245249 (1)